Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 383

1.

Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.

van Waardenburg RC, de Jong LA, van Eijndhoven MA, Verseyden C, Pluim D, Jansen LE, Bjornsti MA, Schellens JH.

J Biol Chem. 2004 Dec 24;279(52):54502-9. Epub 2004 Oct 6.

PMID:
15471886
[PubMed - indexed for MEDLINE]
Free Article
2.

Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.

Janss AJ, Cnaan A, Zhao H, Shpilsky A, Levow C, Sutton L, Phillips PC.

Anticancer Drugs. 1998 Aug;9(7):641-52.

PMID:
9773809
[PubMed - indexed for MEDLINE]
3.

Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines.

Ling YH, Donato NJ, Perez-Soler R.

Cancer Chemother Pharmacol. 2001 Jun;47(6):473-80.

PMID:
11459199
[PubMed - indexed for MEDLINE]
4.

Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.

Kaufmann SH, Peereboom D, Buckwalter CA, Svingen PA, Grochow LB, Donehower RC, Rowinsky EK.

J Natl Cancer Inst. 1996 Jun 5;88(11):734-41.

PMID:
8637027
[PubMed - indexed for MEDLINE]
Free Article
5.

Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives.

Tanizawa A, Kohn KW, Kohlhagen G, Leteurtre F, Pommier Y.

Biochemistry. 1995 May 30;34(21):7200-6.

PMID:
7766631
[PubMed - indexed for MEDLINE]
6.

Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure.

Danks MK, Pawlik CA, Whipple DO, Wolverton JS.

Clin Cancer Res. 1997 Oct;3(10):1731-8.

PMID:
9815557
[PubMed - indexed for MEDLINE]
Free Article
7.

In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells.

Pondarré C, Strumberg D, Fujimori A, Torres-León R, Pommier Y.

Nucleic Acids Res. 1997 Oct 15;25(20):4111-6.

PMID:
9321666
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters.

Takagi K, Dexheimer TS, Redon C, Sordet O, Agama K, Lavielle G, Pierré A, Bates SE, Pommier Y.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3229-38.

PMID:
18089716
[PubMed - indexed for MEDLINE]
Free Article
9.

Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.

Kollmannsberger C, Mross K, Jakob A, Kanz L, Bokemeyer C.

Oncology. 1999;56(1):1-12. Review.

PMID:
9885371
[PubMed - indexed for MEDLINE]
10.

Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.

Ma J, Maliepaard M, Nooter K, Loos WJ, Kolker HJ, Verweij J, Stoter G, Schellens JH.

Br J Cancer. 1998 May;77(10):1645-52.

PMID:
9635842
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Antitumour drugs impede DNA uncoiling by topoisomerase I.

Koster DA, Palle K, Bot ES, Bjornsti MA, Dekker NH.

Nature. 2007 Jul 12;448(7150):213-7. Epub 2007 Jun 24.

PMID:
17589503
[PubMed - indexed for MEDLINE]
12.

Topoisomerase I inhibitors: camptothecins and beyond.

Pommier Y.

Nat Rev Cancer. 2006 Oct;6(10):789-802. Review.

PMID:
16990856
[PubMed - indexed for MEDLINE]
13.

Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients.

Jonsson E, Fridborg H, Nygren P, Larsson R.

Eur J Clin Pharmacol. 1998 Sep;54(7):509-14.

PMID:
9832291
[PubMed - indexed for MEDLINE]
14.

Mechanistic studies of the modulation of cleavage activity of topoisomerase I by DNA adducts of mono- and bi-functional PtII complexes.

Malina J, Vrana O, Brabec V.

Nucleic Acids Res. 2009 Sep;37(16):5432-42. doi: 10.1093/nar/gkp580. Epub 2009 Jul 9.

PMID:
19589806
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.

Garcia-Carbonero R, Supko JG.

Clin Cancer Res. 2002 Mar;8(3):641-61. Review.

PMID:
11895891
[PubMed - indexed for MEDLINE]
Free Article
16.

Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.

Urasaki Y, Laco GS, Pourquier P, Takebayashi Y, Kohlhagen G, Gioffre C, Zhang H, Chatterjee D, Pantazis P, Pommier Y.

Cancer Res. 2001 Mar 1;61(5):1964-9.

PMID:
11280753
[PubMed - indexed for MEDLINE]
Free Article
17.
18.

Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells.

Goldwasser F, Shimizu T, Jackman J, Hoki Y, O'Connor PM, Kohn KW, Pommier Y.

Cancer Res. 1996 Oct 1;56(19):4430-7.

PMID:
8813137
[PubMed - indexed for MEDLINE]
Free Article
19.

Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro.

Ma J, Maliepaard M, Nooter K, Boersma AW, Verweij J, Stoter G, Schellens JH.

Cancer Chemother Pharmacol. 1998;41(4):307-16.

PMID:
9488600
[PubMed - indexed for MEDLINE]
20.

Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells.

Gupta M, Fan S, Zhan Q, Kohn KW, O'Connor PM, Pommier Y.

Clin Cancer Res. 1997 Sep;3(9):1653-60.

PMID:
9815856
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk